[The immunopharmacodynamics of mival].
The authors studied in vitro the immunopharmacodynamics of the new silantrane mival. It was shown that mival possessed mitogenic effects on mononuclear cell proliferation in donors and patients with rheumatoid arthritis. The drug stimulated mononuclear cell proliferation, by acting selectively on T lymphocytes, enhancing T-cell growth lymphokine production, T-suppressor cell activity, and inhibiting prostaglandin E2 production.
Shirinskiĭ
V S
VS
Zhuk
E A
EA
Baryshok
V P
VP
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000276:immunology; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured / Q000166:cytology / Q000187:drug effects; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000187:drug effects; D008934:Mitogens / Q000494:pharmacology; D017646:Organosilicon Compounds / Q000494:pharmacology*; D011837:Radiation-Protective Agents / Q000494:pharmacology*; D013268:Stimulation, Chemical; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
D000276:Adjuvants, Immunologic; D008934:Mitogens; D017646:Organosilicon Compounds; D011837:Radiation-Protective Agents; C033818:1-(chloromethyl)silatrane
Izuchenie immunofarmakodinamiki mivala.